CGS-27023-A (MMI-270), a sulfonamide derivative that has a broad spectrum of inhibition for MMPs, has been shown to attenuate colonic mucosal injury in TNBS-induced colitis in rats by reducing MMP-2 and MMP-9 expression [110]. This evidence concerns the gene MMP9 and colitis.